HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and cancer risk: a meta-analysis.

AbstractBACKGROUND:
Polymorphisms in the cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene have been implicated in susceptibility to cancer, but the many published studies have reported inconclusive results. The objective of the current study was to conduct a meta-analysis investigating the association between polymorphisms in the CTLA-4 gene and the risk of cancer.
METHODS:
The PubMed and EMBASE databases were searched for all articles published up to September 19, 2010 that addressed cancer and polymorphisms, variants, or mutations of CTLA-4. A statistical analysis was performed using proprietary statistical software.
RESULTS:
Three polymorphisms (+49 adenine/guanine [+49A/G], -318 cytosine/thymine [-318C/T], and the +6230G/A polymorphism [CT60]) in 48 case-control studies from 27 articles were analyzed. The results indicated that individuals who carried the +49 G allele (AG + GG) had a 16% decreased risk of cancer compared with homozygotes (+49AA; odds ratio [OR], 0.84; 95% confidence interval [CI], 0.74-0.95). However, there was no significant association between the risk of cancer and the -318C/T polymorphism or the CT60 polymorphism (-318C/T: OR, 1.23; 95% CI, 0.99-1.54 for TT + TC vs CC; CT60: OR, 1.02; 95% CI, 0.80-1.29 for AA + AG vs GG). In further stratified analyses for the +49A/G and -318C/T polymorphisms, the decreased risk of cancer remained in subgroups of Europeans, patients with breast cancer, and patients with lung cancer for the +49A/G polymorphism; whereas an increased risk of cancer was observed among Europeans for the -318C/T polymorphism.
CONCLUSIONS:
Results from the current meta-analysis suggested that the +49A/G and -318C/T polymorphisms in CTLA-4 are risk factors for cancer. To further evaluate gene-gene and gene-environment interactions between CTLA-4 polymorphisms and the risk of cancer, more studies with larger groups of patients will be required.
AuthorsYonggang Zhang, Jie Zhang, Yao Deng, Can Tian, Xiaobo Li, Jin Huang, Hong Fan
JournalCancer (Cancer) Vol. 117 Issue 18 Pg. 4312-24 (Sep 15 2011) ISSN: 1097-0142 [Electronic] United States
PMID21387262 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 American Cancer Society.
Chemical References
  • Antigens, CD
  • CTLA-4 Antigen
  • CTLA4 protein, human
Topics
  • Antigens, CD (genetics)
  • CTLA-4 Antigen
  • Case-Control Studies
  • Genetic Predisposition to Disease
  • Humans
  • Neoplasms (genetics)
  • Polymorphism, Genetic
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: